The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion
Open accessAbstract
In mice, immunoregulatory APCs express the dendritic cell (DC) marker CD11c, and one or more distinctive markers (CD8α, B220, DX5). In this study, we show that expression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced in specific splenic DC subsets when mice were exposed to the synthetic immunomodulatory reagent CTLA4-Ig. CTLA4-Ig did not induce IDO expression in macrophages or lymphoid cells. Induction of IDO completely blocked clonal expansion of T cells from TCR transgenic mice following adoptive transfer, whereas CTLA4-Ig treatment did not block T cell clonal expansion in IDO-deficient recipients. Thus, IDO expression is an inducible feature of specific subsets of DCs, and provides a potential mechanistic explanation for their T cell regulatory properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Self-citationMouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., & Nussenzweig, M. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.769 · Cited by 1,848
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Self-citationCd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance
Steinman, R. M., & Nussenzweig, M. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231606698 · Cited by 1,166
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028
Self-citationTerness, P., Bauer, T. M., Röse, L., Dufter, C., Watzlik, A., Simon, H., & Opelz, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020052 · Cited by 937
Wakkach, A., Fournier, N., Brun, V., Breittmayer, J.-P., Cottrez, F., & Groux, H. (2003) · Immunity · doi:10.1016/s1074-7613(03)00113-4 · Cited by 788
Cited by
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Self-citationImmunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Self-citationInterleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Grazia Roncarolo, M., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,173
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Self-citationIDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Self-citationAryl hydrocarbon receptor ligands in cancer: friend and foe
Murray, I. A., Patterson, A. D., & Perdew, G. H. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3846 · Cited by 883
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Self-citationSharma, M. D., Baban, B., Chandler, P., Hou, D.-Y., Singh, N., Yagita, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 792
Self-citationTryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & Van den Eynde, B. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 703
Nguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
Hou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Self-citationPancreatic cancer: from state-of-the-art treatments to promising novel therapies
Garrido-Laguna, I., & Hidalgo, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 565
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs
Hackstein, H., & Thomson, A. W. (2004) · Nature Reviews Immunology · doi:10.1038/nri1256 · Cited by 545
Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?
Guerin, L. R., Prins, J. R., & Robertson, S. A. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp004 · Cited by 498
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Munn, D. H., Sharma, M. D., & Mellor, A. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4100 · Cited by 457
Self-citationIDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation
Puccetti, P., & Grohmann, U. (2007) · Nature Reviews Immunology · doi:10.1038/nri2163 · Cited by 453
Chen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5396 · Cited by 453
Self-citationKynurenine is an endothelium-derived relaxing factor produced during inflammation
Wang, Y., Liu, H., McKenzie, G., Witting, P. K., Stasch, J.-P., Hahn, M., Changsirivathanathamrong, D., Wu, B. J., Ball, H. J., Thomas, S. R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2092 · Cited by 446
Self-citationInhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Swiecki, M., & Colonna, M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00881.x · Cited by 397
Inhibition of experimental asthma by indoleamine 2,3-dioxygenase
Hayashi, T., Beck, L., Rossetto, C., Gong, X., Takikawa, O., Takabayashi, K., Broide, D. H., Carson, D. A., & Raz, E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421275 · Cited by 344
Phenotypic characterization of regulatory T cells in the human decidua
HEIKKINEN, J., MÖTTÖNEN, M., ALANEN, A., & LASSILA, O. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02441.x · Cited by 343
Manipulating dendritic cell biology for the active immunotherapy of cancer
O'Neill, D. W., Adams, S., & Bhardwaj, N. (2004) · Blood · doi:10.1182/blood-2003-12-4392 · Cited by 339
Infectious tolerance via the consumption of essential amino acids and mTOR signaling
Cobbold, S. P., Adams, E., Farquhar, C. A., Nolan, K. F., Howie, D., Lui, K. O., Fairchild, P. J., Mellor, A. L., Ron, D., & Waldmann, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903919106 · Cited by 336
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Modulating vaccine responses with dendritic cells and Toll‐like receptors
Pulendran, B. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00144.x · Cited by 325
4-1BB-mediated immunotherapy of rheumatoid arthritis
Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., Suh, J. H., Choi, B. K., Vinay, D. S., & Kwon, B. S. (2004) · Nature Medicine · doi:10.1038/nm1107 · Cited by 325
Möttönen, M., Heikkinen, J., Mustonen, L., Isomäki, P., Luukkainen, R., & Lassila, O. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02754.x · Cited by 320
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy
Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C., Orabona, C., Belladonna, M. L., Ayroldi, E., Nocentini, G., et al. (2007) · Nature Medicine · doi:10.1038/nm1563 · Cited by 318
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Vinh, A., Chen, W., Blinder, Y., Weiss, D., Taylor, W. R., Goronzy, J. J., Weyand, C. M., Harrison, D. G., & Guzik, T. J. (2010) · Circulation · doi:10.1161/circulationaha.109.930446 · Cited by 300
Features of responding T cells in cancer and chronic infection
Kim, P. S., & Ahmed, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.005 · Cited by 297
Mellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., & Munn, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5601 · Cited by 290
Self-citationMellor, A. L. (2004) · International Immunology · doi:10.1093/intimm/dxh140 · Cited by 288
Self-citationThe kynurenine pathway of tryptophan degradation as a drug target
Schwarcz, R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.006 · Cited by 265
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Kruse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 270
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2009) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259
Munn, D. H., & Mellor, A. L. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.11.003 · Cited by 259
Self-citationInfectious tolerance and the long-term acceptance of transplanted tissue
Waldmann, H., Adams, E., Fairchild, P., & Cobbold, S. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00406.x · Cited by 177
“IDO, either by catabolism of tryptophan and/or its generation of tryptophan metabolites, can prevent local T-cell function (66).”
BackgroundInvolvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
“As for the metabolite, the expression of kynurenine aminotransferase-I (KATI), the KP enzyme which leads to KYNA formation, is decreased in the SNpc of MPTP treated mice (Knyihar-Csillik et al., 2004).”
BackgroundInfluentialEvolving immunosuppressive microenvironment during human cervical carcinogenesis
Kobayashi, A., Weinberg, V, Darragh, T., & Smith-McCune, K. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.33 · Cited by 136
Tryptophan metabolism: Mechanism-oriented therapy for neurological and psychiatric disorders
Li, D., Yu, S., Long, Y., Shi, A., Deng, J., Ma, Y., Wen, J., Li, X., Liu, S., Zhang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985378 · Cited by 129
Metadata
- Authors
- Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P. A., Iwashima, M., & Munn, D. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08
- Volume
- 171
- Issue
- 4
- Pages
- 1652-1655
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1554937135
- Cited by
- 455
- References
- 34
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.